Effexor Plaintiffs Seek to Drop 40% of Lawsuits from MDL
Law360 reports that the plaintiffs in a multidistrict litigation involving Effexor, a depression and anxiety medication manufactured by Wyeth Pharmaceuticals Inc., have sought to dismiss 26 lawsuits targeting the Pfizer unit over the drug’s alleged risk of birth defects. The multidistrict litigation is In re: Effexor (Venlafaxine Hydrochloride) Products Liability Litigation, MDL 2458.
Judge Cynthia Rufe, the federal judge presiding over the Effexor MDL in the Eastern District of Pennsylvania, has already granted plaintiffs’ dismissals in at least 8 of these cases. Before these dismissals, there were a total of 65 lawsuits in the MDL. Plaintiffs in the MDL have been filing stipulations for dismissal without prejudice since January 22.
Judge Rufe also presides over the Zoloft multidistrict litigation (In re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation, MDL 2342) in the Eastern District of Pennsylvania, which involves parallel claims with Wyeth and parent company Pfizer, Inc. in association with the antidepressant medication, Zoloft, and its alleged links to serious birth defects. According to the most recent report from the Judicial Panel on Multidistrict Litigation, there are over 500 Zoloft lawsuits currently pending in MDL 2342.
The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.